Peptides DB
Research-centric peptide and protocol reference hub
Study 28 of 30Liraglutide literatureLife sciences · Observational2026

Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner.

Inhibition of GHSR may enhance the glucose-lowering effects of liraglutide in male mice, but further research is needed to determine the relevance of these findings in humans.

Read at Life sciencesAdd to compare

Where it sits

this study against the rest of the liraglutide corpus
6
Preclinical
16
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This study investigated the effects of liraglutide on glycemia in male mice with genetic GHSR deficiency and pharmacological GHSR blockade. It was found that liraglutide reduced glycemia more effectively in GHSR-null male mice than in control mice under certain conditions. The study also explored the cellular mechanisms involved using murine islets and human pancreatic tissue.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Life sciences supplied them

<h4>Aims</h4>Liraglutide is a glucagon-like peptide-1 receptor (GLP-1R) agonist that lowers glycemia and is used to treat type 2 diabetes (T2D) and obesity. Activation of the growth hormone secretagogue receptor (GHSR) increases glycemia. We aimed to determine whether GHSR inhibition enhances the glucose-lowering effects of liraglutide.<h4>Materials and methods</h4>We investigated the acute glucose-lowering effects of liraglutide in mice with genetic GHSR deletion or pharmacological GHSR blockade under fed, fasting, and postprandial conditions. We also examined the potential cellular basis of this interaction in murine islets using transcriptomic and immunolabeling approaches and in human pancreatic tissue using a publicly available transcriptomic dataset.<h4>Key findings</h4>Liraglutide similarly reduced glycemia in ad libitum-fed GHSR-null and control mice. Following food deprivation, liraglutide more effectively attenuated postprandial increases in glycemia in male, but not female, GHSR-null mice than in control mice. Liraglutide reduced glycemia in fasted GHSR-null male mice but not in WT males. In male mice, pretreatment with a LEAP2 (liver-expressed antimicrobial peptide 2) analog, an endogenous GHSR antagonist and inverse agonist, enhanced the glucose-lowering effects of liraglutide under postprandial and fasting conditions. GHSR and GLP-1R showed limited co-expression in murine islets. In human islets, their co-expression was also limited and enriched in δ-cells, but was also detected in β-cells, where the proportion of GHSR<sup>+</sup>/GLP-1R<sup>+</sup> cells was higher in donors with T2D.<h4>Significance</h4>GHSR inhibition enhances liraglutide's glucose-lowering effects in a sex-dependent manner, highlighting GHSR as a potential target to improve GLP-1R agonist efficacy.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Liraglutide corpus

BUtilization of and gross spending on anti-obesity GLP-1 receptor agonists in state Medicaid programs, 2021 to 2026: a brand-level analysis of State Drug Utilization Databiorxiv-preprint · 2023 · Gross reimbursement increased from $24.7 million in 2021 to $4.44 billion in 2025.reviewDComparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.Diabetes, obesity & metabolism · 2026 · HR = 1.251, 95% CI: 1.080-1.450 for liraglutide compared to non-GLP-1RA treatments.reviewAGenetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial studybiorxiv-preprint · 2026 · n=134138 · Incretin receptor agonists increased serious fibro-capsular events with a Peto OR of 3·88, 95% CI 1·83–8·25; P = 4·1 × 10 −4.HumanBReal-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.Metabolism open · 2026 · n=1499 · Mean HbA1c decreased by 1.66 percentage points; P < 0.001.HumanBEconomic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.Journal of diabetes and metabolic disorders · 2026 · Incremental cost-effectiveness ratio of US$34,423.89/QALY for tirzepatide compared with semaglutide.reviewDInflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.review